Back to Executive Team

Jodie Morrison

Interim Chief Executive Officer, Board Member

Jodie P. Morrison was named our interim Chief Executive Officer on April 30, 2018. She has served on our Board of Directors since June 2016. In addition, Jodie currently sits on the board of Aileron Therapeutics (ALRN) and Novus Therapeutics (NVUS) and is a consultant to the industry. She served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. from March 2013 until May 2017. From December 2006 until March 2013, Ms. Morrison held other senior positions with Tokai, including Chief Operating Officer, Head of Clinical Affairs and Program Operations and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in Clinical Operations and Medical Affairs at Dyax Corporation, Curis, Inc. and Diacrin, Inc. Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from the Boston University School of Medicine and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

You are leaving

You are leaving, a website of Keryx Biopharmaceuticals, Inc. Keryx does not review or control the content of non-Keryx websites, and this hyperlink does not constitute an endorsement by Keryx of the site’s content. Keryx’s privacy procedures do not apply to the owners of a non-Keryx website.